p chk1  (Santa Cruz Biotechnology)

Journal: bioRxiv

Article Title: Potentiation of EGFR mutant lung cancer treatment targeting replication stress

doi: 10.1101/2025.04.18.649510

Figure Lengend Snippet: Impact of RPAi treatment on osimertinib-dependent EGFR blockade. (A) PC9 cells were treated with 30nM osimertinib and 1.5mM NERx-329 for the indicated times, cells were collected, lysed and loaded on SDS-PAGE and subjected to western blot analysis for p-EGFR, EGFR and GAPDH as described in “methods and Materials”. (B) HCC4006 cells were treated with 8 nM osimertinib and 5 mM NERx-329 as indicated and processed as described.

Article Snippet: The membranes were incubated with 5% w/v non-fat dry milk for 1h at room temperature then incubated with primary antibodies to p-Chk1, Chk1, p-EGFR, EGFR, p-ATR, ATR, p-Chk2, Chk2, and GAPDH following manufacturers (Cell Signaling Technology, Danvers, MA, USA,) at the manufacturer suggested dilution.

Techniques: SDS Page, Western Blot